Emil D. Kakkis
CIK: 0001248093
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Ultragenyx Pharmaceutical Inc.
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Apr 16, 2026RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct76.7K shares- - Mar 2, 2026RARE
Ultragenyx Pharmaceutical Inc.
Sale(S)Direct54.4K shares at avg. $22.80$1.2M - Mar 1, 2026RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct71.2K shares- - Mar 3, 2025RARE
Ultragenyx Pharmaceutical Inc.
Sale(S)Direct73.4K shares at avg. $42.10$3.1M - Mar 1, 2025RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct43.3K shares- - Mar 1, 2025RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct107.3K shares- - Feb 28, 2025RARE
Ultragenyx Pharmaceutical Inc.
Sale(S)Indirect25K shares at avg. $42.48$1.1M - Dec 30, 2024RARE
Ultragenyx Pharmaceutical Inc.
Sale(S)Indirect11.7K shares at avg. $42.23$495K - Dec 10, 2024RARE
Ultragenyx Pharmaceutical Inc.
Sale(S)Indirect8.3K shares at avg. $50.00$414K - Dec 9, 2024RARE
Ultragenyx Pharmaceutical Inc.
Gift(G)Indirect20K shares- - Sep 3, 2024RARE
Ultragenyx Pharmaceutical Inc.
Sale(S)Indirect20K shares at avg. $55.85$1.1M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 16, 2026 | RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 76,745 | - | $0 | Direct |
| Mar 2, 2026 | RARE Ultragenyx Pharmaceutical Inc. | Sale(S) | 54,404 | $22.80 | $1,240,411 | Direct |
| Mar 1, 2026 | RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 71,177 | - | $0 | Direct |
| Mar 3, 2025 | RARE Ultragenyx Pharmaceutical Inc. | Sale(S) | 73,434 | $42.10 | $3,091,571 | Direct |
| Mar 1, 2025 | RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 43,268 | - | - | Direct |
| Mar 1, 2025 | RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 107,292 | - | - | Direct |
| Feb 28, 2025 | RARE Ultragenyx Pharmaceutical Inc. | Sale(S) | 25,000 | $42.48 | $1,062,000 | Indirect |
| Dec 30, 2024 | RARE Ultragenyx Pharmaceutical Inc. | Sale(S) | 11,727 | $42.23 | $495,231 | Indirect |
| Dec 10, 2024 | RARE Ultragenyx Pharmaceutical Inc. | Sale(S) | 8,273 | $50.00 | $413,650 | Indirect |
| Dec 9, 2024 | RARE Ultragenyx Pharmaceutical Inc. | Gift(G) | 20,000 | - | $0 | Indirect |
| Sep 3, 2024 | RARE Ultragenyx Pharmaceutical Inc. | Sale(S) | 20,000 | $55.85 | $1,117,000 | Indirect |
1-11 of 11 transactions
About KAKKIS EMIL D
KAKKIS EMIL D (SEC CIK 0001248093) files insider reports with the SEC as President & CEO of Ultragenyx Pharmaceutical Inc. (RARE).
Signal8 holds 6 ownership filings by KAKKIS EMIL D, all Form 4s, filed between Sep 5, 2024 and Apr 20, 2026. Those filings report 11 transactions, from Sep 3, 2024 to Apr 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on KAKKIS EMIL D's filings is in NOVATO, CA.
Recent filings by KAKKIS EMIL D
- Apr 16, 2026: Grant or award of RARE shares (Form 4, code A).
- Mar 2, 2026: Open-market sale of RARE shares (Form 4, code S).
- Mar 1, 2026: Grant or award of RARE shares (Form 4, code A).
- Mar 3, 2025: Open-market sale of RARE shares (Form 4, code S).
- Mar 1, 2025: Grants or awards of RARE shares (2 lines, Form 4, code A).
Other insiders filing for Ultragenyx Pharmaceutical Inc. (RARE)
- Horn Howard, Chief Financial Officer
- Huizenga Theodore Alan, SVP, Chief Accounting Officer
- Parschauer Karah Herdman, EVP and Chief Legal Officer
- Sanders Corazon (Corsee) D., Director
- Fust Matthew K, Director
- SULIMAN SHEHNAAZ, Director